Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient monitoring, proactive adverse effect management, and adapting protocols ...

Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Birmingham researchers have received £230k of translational funding from Cancer Research Horizons to develop a prototype for a new test to monitor people at risk of developing the blood cancer ...

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence.

A large U.S. registry study of ide-cel CAR-T therapy in relapsed/refractory multiple myeloma shows strong response rates and a safety profile comparable to clinical trials—even among older and ...

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible ...

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with ...